EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC)

Fedor Wadi Richani Meinhardt, Mijail I Zambrano Iglesias, María P Fernández Gómez iD, Jesús F Saltaren Fonseca, Atif Hussein, Luis E Raez iD

International Journal of Molecular Sciences · 29.05.2026 · 27 (11) · 4910

DOI: 10.3390/ijms27114910 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 29.05.2026. Verfasst von Fedor Wadi Richani Meinhardt und 5 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Cancer Institute, Pembroke Pines, FL 33027, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Erb-b2 Receptor Tyrosine Kinases, Lung Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This review discusses the role of human epidermal growth factor receptor 2 (HER2/ERBB2) as a key oncogenic driver in non-small cell lung cancer (NSCLC), including exon 20 activating mutations, gene amplification, and protein overexpression. These forms differ in their biological effects and predictive value, but HER2 mutations, especially exon 20 insertions, are the primary oncogenic mechanism. Regarding diagnosis, Next-Generation Sequencing (NGS) is used to identify mutations, whereas Immunohistochemistry (IHC) and in situ hybridization are used to assess HER2 expression. Concerning treatment, in advanced HER2-positive, Non-Squamous NSCLC tumors, the first-line treatment is Platinum-based + Pemetrexed chemotherapy, with or without immunotherapy, because no HER2-targeted antibody therapy has yet been approved for initial treatment. After progression, HER2-targeted antibody-drug conjugates like Trastuzumab-Deruxtecan and Ado Trastuzumab-Emtansine may offer patients clinical benefits. New HER2-selective tyrosine kinase inhibitors, such as zongertinib and sevabertinib, have shown promising results, including patients previously treated with antibody–drug conjugates (ADCs). Recent advances, including next-generation ADCs such as SHR-A1811 and A166, and bispecific antibodies, such as zenocutuzumab for NRG1 fusion–positive disease, which are also expanding treatment options. Overall, advances in diagnostics and new targeted therapies are changing how HER2-altered NSCLC is treated and are helping to make care more personalized.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungErb-b2 Receptor Tyrosine KinasesLung NeoplasmsProtein Kinase InhibitorsHumansMolecular Targeted TherapyMutation

Stichwörter der Autor:innen

ERBB2HER2antibody–drug conjugateexon 20 insertionimmunohistochemistrynext-generation sequencingnon-small cell lung cancersevabertinibtrastuzumab deruxtecanzongertinib

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Memorial Cancer Institute, Pembroke Pines, FL 33027, USA.
  • Independent Researcher, Rio de Janeiro 22210-030, Brazil.
  • Institute for Human Health and Disease Intervention, Florida Atlantic University (FAU), Jupiter, FL 33458, USA.

ORCID-Profile: María P Fernández Gómez, Luis E Raez

Zitieren

APA

Richani Meinhardt, F. W., Zambrano Iglesias, M. I., Fernández Gómez, M. P., Saltaren Fonseca, J. F., Hussein, A., & Raez, L. E. (2026). HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC). International Journal of Molecular Sciences, 27(11), 4910. https://doi.org/10.3390/ijms27114910

Vancouver

Richani Meinhardt FW, Zambrano Iglesias MI, Fernández Gómez MP, Saltaren Fonseca JF, Hussein A, Raez LE. HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC). International Journal of Molecular Sciences. 2026;27(11):4910. doi:10.3390/ijms27114910

BibTeX
@article{RichaniMeinhardt2026,
  author = {Richani Meinhardt, Fedor Wadi and Zambrano Iglesias, Mijail I and Fernández Gómez, María P and Saltaren Fonseca, Jesús F and Hussein, Atif and Raez, Luis E},
  title = {HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC)},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {11},
  pages = {4910},
  doi = {10.3390/ijms27114910}
}
Kostenlos starten →